When do firms benefit from joint price and lead-time competition?

被引:5
|
作者
Sun, Yiqi [1 ]
Wu, Zhengping [2 ]
Zhu, Wanshan [3 ]
机构
[1] Tsinghua Univ, Dept Ind Engn, Beijing 100084, Peoples R China
[2] Syracuse Univ, Whitman Sch Management, Syracuse, NY 13244 USA
[3] Renmin Univ China, Sch Business, Beijing 100872, Peoples R China
基金
中国国家自然科学基金;
关键词
Supply chain management; Pricing; Lead-time quotation; Competition; SUPPLY CHAIN; CAPACITY; DECISIONS; PRODUCT; COORDINATION; INDUSTRIES; QUOTATION; DEMAND;
D O I
10.1016/j.ejor.2022.01.008
中图分类号
C93 [管理学];
学科分类号
12 ; 1201 ; 1202 ; 120202 ;
摘要
Motivated by the observation that more and more firms are now using lead-time guarantee as a new competitive weapon to attract customers, we study firms' optimal decisions in prices and lead-time quotations when they compete in these two dimensions for demand. We formulate a simultaneous game between multiple firms that sell substitutable products to the same market, and customer demand is determined by both prices and lead-time quotations of all firms. We fully characterize the existence and uniqueness of the Nash equilibrium, and use analytical results supplemented by comprehensive numerical examples to understand the impact of competition. Our research yields two key counterintuitive findings. First, although on the surface price and lead-time shape the demand function in a similar fashion, competition in these two dimensions drives equilibrium price and lead-time quotation in opposite directions. In particular, price competition decreases price but increases lead-time quotation, whereas lead-time competition increases price but decreases lead-time quotation. Second, under joint price and lead-time competition, if the relative price and lead-time competition intensities are disparate, firms can benefit from increased competition in the weaker dimension. The intuition is that increased competition in the weaker dimension diffuses the tensions between the firms in the stronger competition dimension, mitigating its negative impact on profit. To the best of our knowledge, we are among the first to identify conditions under which firms can gain from intensified competition. (C) 2022 Elsevier B.V. All rights reserved.
引用
收藏
页码:497 / 517
页数:21
相关论文
共 50 条
  • [41] Do consumers benefit from tighter price cap regulation?
    Kang, JS
    Weisman, DL
    Zhang, MY
    [J]. ECONOMICS LETTERS, 2000, 67 (01) : 113 - 119
  • [42] Impact of hepatocellular carcinoma aetiology and liver function on the benefit of surveillance: A novel approach for the adjustment of lead-time bias
    Toyoda, Hidenori
    Kumada, Takashi
    Tada, Toshifumi
    Mizuno, Kazuyuki
    Hiraoka, Atsushi
    Tsuji, Kunihiko
    Ishikawa, Toru
    Akita, Tomoyuki
    Tanaka, Junko
    [J]. LIVER INTERNATIONAL, 2018, 38 (12) : 2260 - 2268
  • [43] Standard vs. Custom Products: Variety, Lead Time, and Price Competition
    Xia, Nan
    Rajagopalan, S.
    [J]. MARKETING SCIENCE, 2009, 28 (05) : 887 - 900
  • [44] Do Firms Benefit from Concentrating their Borrowing? Evidence from the Great Recession
    Gobbi, Giorgio
    Sette, Enrico
    [J]. REVIEW OF FINANCE, 2014, 18 (02) : 527 - 560
  • [45] Do dependent suppliers benefit from buying firms' sustainability practices?
    Sancha, Cristina
    Wong, Christina W. Y.
    Gimenez, Cristina
    [J]. JOURNAL OF PURCHASING AND SUPPLY MANAGEMENT, 2019, 25 (04)
  • [46] Science or graduates: How do firms benefit from the proximity of universities?
    Leten, Bart
    Landoni, Paolo
    Van Looy, Bart
    [J]. RESEARCH POLICY, 2014, 43 (08) : 1398 - 1412
  • [47] When do firms get ideas from hiring PhDs?
    Buenstorf, Guido
    Heinisch, Dominik P.
    [J]. RESEARCH POLICY, 2020, 49 (03)
  • [48] High-cost domestic joint ventures and international competition: Do domestic firms gain?
    Spencer, BJ
    Raubitschek, RS
    [J]. INTERNATIONAL ECONOMIC REVIEW, 1996, 37 (02) : 315 - 340
  • [49] Lead-time from diagnosis to start of radiation shortened by 44% for head and neck cancer when patients go through a multidisciplinary clinic
    Parzuchowski, J. S.
    Jordon, J.
    Burgess, L.
    Witsell, M.
    Sobol, L.
    Rontal, M.
    Balaraman, S.
    Ignatius, R.
    Venuturumilli, P.
    Krauss, D.
    Chen, P.
    Fontanesi, J.
    Akervall, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [50] When and how do patients benefit from clinical research?
    Raspe, H
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2005, 130 (28-29) : 1701 - 1705